Literature DB >> 14762850

Prevention and treatment of hepatocellular carcinoma.

Masao Omata1, Haruhiko Yoshida.   

Abstract

Viral hepatitis, by either hepatitis C virus (HCV) or hepatitis B virus (HBV), is the dominant cause of hepatocellular carcinoma (HCC). This is to say that HCC may be prevented by controlling viral infection. Horizontal transmission of HCV has become obsolete owing to the discovery of the virus. Vertical transmission of HBV during delivery has been effectively prevented by vaccination and immunization of neonates. The efficacy of interferon therapy against HCV was recently much improved. We now possess several powerful antiviral drugs against HBV. There has been progress also in the treatment of HCC, and together with advances in diagnostics facilitating HCC detection at an early stage, tumor nodules can often be completely removed either by medical ablation or surgical resection. Nevertheless, recurrence of HCC after apparently curative treatment is extraordinarily frequent, since the remaining liver is still at a particularly high risk of HCC. An effective treatment of HCC should include measures to control de novo carcinogenesis.

Entities:  

Mesh:

Year:  2004        PMID: 14762850     DOI: 10.1002/lt.20046

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

1.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

Review 2.  Evidence regarding a stem cell origin of hepatocellular carcinoma.

Authors:  Thomas Shupe; Bryon E Petersen
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  Successful treatment with lamivudine may correlate with reduction of serum ferritin levels in the patients with chronic hepatitis and liver cirrhosis type B.

Authors:  Shogo Ohkoshi; Akira Yoshimura; Satoshi Yamamoto; Masahiko Yano; So Kurita; Kazuhide Yamazaki; Yo-Hei Aoki; Satoshi Yamagiwa; Hiroto Wakabayashi; Motoya Sugiyama; Tohru Takahashi; Tohru Ishikawa; Yasunobu Matsuda; Takafumi Ichida; Tomoteru Kamimura; Yutaka Aoyagi
Journal:  Hepatol Int       Date:  2008-07-25       Impact factor: 6.047

4.  Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis.

Authors:  Takashi Someya; Kenji Ikeda; Satoshi Saitoh; Masahiro Kobayashi; Tetsuya Hosaka; Hitomi Sezaki; Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Yasuji Arase; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2007-02-06       Impact factor: 7.527

5.  Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection.

Authors:  Y-R Deng; K Yoshida; Q L Jin; M Murata; T Yamaguchi; K Tsuneyama; Y Moritoki; J Q Niu; K Matsuzaki; Z-X Lian
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

Review 6.  Early liver cancer: concepts, diagnosis, and management.

Authors:  Hideo Yoshida; Haruhiko Yoshida; Shuichiro Shiina; Masao Omata
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

Review 7.  Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells.

Authors:  Koichi Matsuzaki
Journal:  Cell Tissue Res       Date:  2011-05-31       Impact factor: 5.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.